Literature DB >> 29466721

Insights from molecular dynamics simulations to exploit new trends for the development of improved opioid drugs.

Marta Filizola1.   

Abstract

Having accidental deaths from opioid overdoses almost quadrupled over the past fifteen years, there is a strong need to develop new, non-addictive medications for chronic pain to stop one of the deadliest epidemics in American history. Given their potentially fewer on-target overdosing risks and other adverse effects compared to classical opioid drugs, attention has recently shifted to opioid allosteric modulators and G protein-biased opioid agonists as likely drug candidates to prevent and/or reverse opioid overdoses. Understanding how these molecules bind and activate their receptors at an atomistic level is key to developing them into effective new therapeutics, and molecular dynamics-based strategies are contributing tremendously to this understanding.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Allosteric modulator; Biased agonism; Functional selectivity; Receptor; Structure

Mesh:

Substances:

Year:  2018        PMID: 29466721      PMCID: PMC6098741          DOI: 10.1016/j.neulet.2018.02.037

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  61 in total

Review 1.  Allosteric modulation of G protein-coupled receptors: a pharmacological perspective.

Authors:  Peter Keov; Patrick M Sexton; Arthur Christopoulos
Journal:  Neuropharmacology       Date:  2010-07-15       Impact factor: 5.250

2.  A randomized, phase 2 study investigating TRV130, a biased ligand of the μ-opioid receptor, for the intravenous treatment of acute pain.

Authors:  Eugene R Viscusi; Lynn Webster; Michael Kuss; Stephen Daniels; James A Bolognese; Seth Zuckerman; David G Soergel; Ruth Ann Subach; Emily Cook; Franck Skobieranda
Journal:  Pain       Date:  2016-01       Impact factor: 6.961

3.  HTMD: High-Throughput Molecular Dynamics for Molecular Discovery.

Authors:  S Doerr; M J Harvey; Frank Noé; G De Fabritiis
Journal:  J Chem Theory Comput       Date:  2016-03-16       Impact factor: 6.006

4.  Antinociceptive effects of herkinorin, a MOP receptor agonist derived from salvinorin A in the formalin test in rats: new concepts in mu opioid receptor pharmacology: from a symposium on new concepts in mu-opioid pharmacology.

Authors:  Kenneth Lamb; Kevin Tidgewell; Denise S Simpson; Laura M Bohn; Thomas E Prisinzano
Journal:  Drug Alcohol Depend       Date:  2011-11-26       Impact factor: 4.492

5.  Structure-based discovery of opioid analgesics with reduced side effects.

Authors:  Aashish Manglik; Henry Lin; Dipendra K Aryal; John D McCorvy; Daniela Dengler; Gregory Corder; Anat Levit; Ralf C Kling; Viachaslau Bernat; Harald Hübner; Xi-Ping Huang; Maria F Sassano; Patrick M Giguère; Stefan Löber; Grégory Scherrer; Brian K Kobilka; Peter Gmeiner; Bryan L Roth; Brian K Shoichet
Journal:  Nature       Date:  2016-08-17       Impact factor: 49.962

6.  The 'allosteric modulator' SCH-202676 disrupts G protein-coupled receptor function via sulphydryl-sensitive mechanisms.

Authors:  Anna M Lewandowicz; Jouko Vepsäläinen; Jarmo T Laitinen
Journal:  Br J Pharmacol       Date:  2006-02       Impact factor: 8.739

Review 7.  New concepts in drug discovery: collateral efficacy and permissive antagonism.

Authors:  Terry Kenakin
Journal:  Nat Rev Drug Discov       Date:  2005-11       Impact factor: 84.694

8.  Synthetic and Receptor Signaling Explorations of the Mitragyna Alkaloids: Mitragynine as an Atypical Molecular Framework for Opioid Receptor Modulators.

Authors:  Andrew C Kruegel; Madalee M Gassaway; Abhijeet Kapoor; András Váradi; Susruta Majumdar; Marta Filizola; Jonathan A Javitch; Dalibor Sames
Journal:  J Am Chem Soc       Date:  2016-05-18       Impact factor: 15.419

9.  Structural basis for bifunctional peptide recognition at human δ-opioid receptor.

Authors:  Gustavo Fenalti; Nadia A Zatsepin; Cecilia Betti; Patrick Giguere; Gye Won Han; Andrii Ishchenko; Wei Liu; Karel Guillemyn; Haitao Zhang; Daniel James; Dingjie Wang; Uwe Weierstall; John C H Spence; Sébastien Boutet; Marc Messerschmidt; Garth J Williams; Cornelius Gati; Oleksandr M Yefanov; Thomas A White; Dominik Oberthuer; Markus Metz; Chun Hong Yoon; Anton Barty; Henry N Chapman; Shibom Basu; Jesse Coe; Chelsie E Conrad; Raimund Fromme; Petra Fromme; Dirk Tourwé; Peter W Schiller; Bryan L Roth; Steven Ballet; Vsevolod Katritch; Raymond C Stevens; Vadim Cherezov
Journal:  Nat Struct Mol Biol       Date:  2015-02-16       Impact factor: 15.369

10.  Multiple Fentanyl Overdoses - New Haven, Connecticut, June 23, 2016.

Authors:  Anthony J Tomassoni; Kathryn F Hawk; Karen Jubanyik; Daniel P Nogee; Thomas Durant; Kara L Lynch; Rushaben Patel; David Dinh; Andrew Ulrich; Gail D'Onofrio
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2017-02-03       Impact factor: 17.586

View more
  5 in total

Review 1.  Molecular Basis of Opioid Action: From Structures to New Leads.

Authors:  Aashish Manglik
Journal:  Biol Psychiatry       Date:  2019-09-12       Impact factor: 13.382

Review 2.  Comprehensive overview of biased pharmacology at the opioid receptors: biased ligands and bias factors.

Authors:  Jolien De Neve; Thomas M A Barlow; Dirk Tourwé; Frédéric Bihel; Frédéric Simonin; Steven Ballet
Journal:  RSC Med Chem       Date:  2021-04-21

3.  In vitro and in vivo Pharmacological Activities of 14-O-Phenylpropyloxymorphone, a Potent Mixed Mu/Delta/Kappa-Opioid Receptor Agonist With Reduced Constipation in Mice.

Authors:  Roberta Lattanzi; Silvia Rief; Helmut Schmidhammer; Lucia Negri; Mariana Spetea
Journal:  Front Pharmacol       Date:  2018-08-31       Impact factor: 5.810

Review 4.  Biased, Bitopic, Opioid-Adrenergic Tethered Compounds May Improve Specificity, Lower Dosage and Enhance Agonist or Antagonist Function with Reduced Risk of Tolerance and Addiction.

Authors:  Robert Root-Bernstein
Journal:  Pharmaceuticals (Basel)       Date:  2022-02-10

Review 5.  Development of Diphenethylamines as Selective Kappa Opioid Receptor Ligands and Their Pharmacological Activities.

Authors:  Helmut Schmidhammer; Filippo Erli; Elena Guerrieri; Mariana Spetea
Journal:  Molecules       Date:  2020-11-02       Impact factor: 4.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.